CMS decision opens ‘massive’ patient pool for Medtronic, says BTIG

TipRanks

Sat, Jul 12, 2025, 9:50 AM 1 min read

BTIG analyst Ryan Zimmerman keeps a Neutral rating on Medtronic (MDT) after Centers for Medicare and Medicaid Services provided a proposed national coverage decision for renal denervation. As anticipated, CMS is proposing to cover renal denervation for uncontrolled hypertension, the analyst tells investors in a research note. BTIG says that while the news was expected, it is still a win for Medtronic. The company has been preparing sites for coverage with the launch of Symplicity Spyral, the firm points out. BTIG believes the decision opens up Medtronic to a “massive” potential patient pool.

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

• Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on MDT:

Disclaimer & DisclosureReport an Issue

• Unusually active option classes on open July 11th

• Medtronic rallies after CMS announces request to cover renal denervation

• CMS coverage decision a win for Medtronic, says JPMorgan

• CMS proposal for reimbursement ‘seems positive’ for Medtronic, says Stifel

• Medtronic’s Renal Denervation Opportunity: Hold Rating Amid Challenges and Potential Growth